Abstract
Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase- 5 (PDE-5) inhibitors. L. Maresca, M. D'Agostino, L. Castaldo, A. Vitelli, M. Mancini, G. Torella, R. Lucci, G. Albano, D. Del Forno, M. Ferro, V. Altieri, F. Giallauria, C. Vigorito. Introduction. Erectile dysfunction (ED) affects about 50% of males aged 40-70 years old. ED shares with atherosclerotic disease several common risk factors; therefore, it may be considered a surrogate marker of atherosclerosis. Sincephosphodiesterase-5 inhibitors are well known pharmacologic agents capable of significant improvement in ED, we designed this study to evaluate whether exercise training is of added value in patients with ED who are already on PDE-5 inhibitors. Methods. We recruited 20 male patients affected by ED with metabolic syndrome.At baseline, all patients underwent Cardio-Pulmonary Exercise Testing (CPET) and the International Index of Erectile Function (IIEF) test.After the initial evaluation, patients were subdivided into two groups: tadalafil group (group T, n=10), who were maintained only on tadalafil therapy, and a tadalafil/exercise training group (T/E group, n=10)who continued tadalafil but in addition underwent a2-month structured exercise training program. Results. Basal anthropometric characteristics of study population showed no significant differences. Although bothgroups showed at 2 months an improvement of the IIEF score, thiswas more evident in the T/E group (T group: 11.2 vs 14.2, P=0.02; T/E group: 10.8 vs 20.1, P2peak) only in the T/E group patients (T group: 13.63±2.03 vs 14.24±2.98 mL/kg/min; P=0.521; T/E group: 13.41±2.97 vs 16.58±3.17 mL/kg/min; P=0.006). A significant correlation was found between the changes in VO2peak and the modifications in IIEF score (r=0.575; P=0.001). Conclusion. Exercise training in ED patients treated with PDE-5 inhibitors is of added valuesincefurther improves ED, as evaluated by IIEF score, and increases functional capacity.
| Original language | English |
|---|---|
| Pages (from-to) | 177-183 |
| Number of pages | 7 |
| Journal | Monaldi Archives for Chest Disease - Cardiac Series |
| Volume | 80 |
| Issue number | 4 |
| Publication status | Published - Dec 1 2013 |
Fingerprint
Keywords
- Erectile dysfunction
- Erectile dysfunction therapy
- Exercise training
- Metabolic syndrome
- Phosphodiesterase-5
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pulmonary and Respiratory Medicine
Cite this
Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. / Maresca, Luigi; D'Agostino, Mariantonietta; Castaldo, Luigi; Vitelli, Alessandra; Mancini, Maria; Torella, Giorgio; Lucci, Rosa; Albano, Giovanna; Del Forno, Domenico; Ferro, Matteo; Altieri, Vincenzo; Giallauria, Francesco; Vigorito, Carlo.
In: Monaldi Archives for Chest Disease - Cardiac Series, Vol. 80, No. 4, 01.12.2013, p. 177-183.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors
AU - Maresca, Luigi
AU - D'Agostino, Mariantonietta
AU - Castaldo, Luigi
AU - Vitelli, Alessandra
AU - Mancini, Maria
AU - Torella, Giorgio
AU - Lucci, Rosa
AU - Albano, Giovanna
AU - Del Forno, Domenico
AU - Ferro, Matteo
AU - Altieri, Vincenzo
AU - Giallauria, Francesco
AU - Vigorito, Carlo
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase- 5 (PDE-5) inhibitors. L. Maresca, M. D'Agostino, L. Castaldo, A. Vitelli, M. Mancini, G. Torella, R. Lucci, G. Albano, D. Del Forno, M. Ferro, V. Altieri, F. Giallauria, C. Vigorito. Introduction. Erectile dysfunction (ED) affects about 50% of males aged 40-70 years old. ED shares with atherosclerotic disease several common risk factors; therefore, it may be considered a surrogate marker of atherosclerosis. Sincephosphodiesterase-5 inhibitors are well known pharmacologic agents capable of significant improvement in ED, we designed this study to evaluate whether exercise training is of added value in patients with ED who are already on PDE-5 inhibitors. Methods. We recruited 20 male patients affected by ED with metabolic syndrome.At baseline, all patients underwent Cardio-Pulmonary Exercise Testing (CPET) and the International Index of Erectile Function (IIEF) test.After the initial evaluation, patients were subdivided into two groups: tadalafil group (group T, n=10), who were maintained only on tadalafil therapy, and a tadalafil/exercise training group (T/E group, n=10)who continued tadalafil but in addition underwent a2-month structured exercise training program. Results. Basal anthropometric characteristics of study population showed no significant differences. Although bothgroups showed at 2 months an improvement of the IIEF score, thiswas more evident in the T/E group (T group: 11.2 vs 14.2, P=0.02; T/E group: 10.8 vs 20.1, P2peak) only in the T/E group patients (T group: 13.63±2.03 vs 14.24±2.98 mL/kg/min; P=0.521; T/E group: 13.41±2.97 vs 16.58±3.17 mL/kg/min; P=0.006). A significant correlation was found between the changes in VO2peak and the modifications in IIEF score (r=0.575; P=0.001). Conclusion. Exercise training in ED patients treated with PDE-5 inhibitors is of added valuesincefurther improves ED, as evaluated by IIEF score, and increases functional capacity.
AB - Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase- 5 (PDE-5) inhibitors. L. Maresca, M. D'Agostino, L. Castaldo, A. Vitelli, M. Mancini, G. Torella, R. Lucci, G. Albano, D. Del Forno, M. Ferro, V. Altieri, F. Giallauria, C. Vigorito. Introduction. Erectile dysfunction (ED) affects about 50% of males aged 40-70 years old. ED shares with atherosclerotic disease several common risk factors; therefore, it may be considered a surrogate marker of atherosclerosis. Sincephosphodiesterase-5 inhibitors are well known pharmacologic agents capable of significant improvement in ED, we designed this study to evaluate whether exercise training is of added value in patients with ED who are already on PDE-5 inhibitors. Methods. We recruited 20 male patients affected by ED with metabolic syndrome.At baseline, all patients underwent Cardio-Pulmonary Exercise Testing (CPET) and the International Index of Erectile Function (IIEF) test.After the initial evaluation, patients were subdivided into two groups: tadalafil group (group T, n=10), who were maintained only on tadalafil therapy, and a tadalafil/exercise training group (T/E group, n=10)who continued tadalafil but in addition underwent a2-month structured exercise training program. Results. Basal anthropometric characteristics of study population showed no significant differences. Although bothgroups showed at 2 months an improvement of the IIEF score, thiswas more evident in the T/E group (T group: 11.2 vs 14.2, P=0.02; T/E group: 10.8 vs 20.1, P2peak) only in the T/E group patients (T group: 13.63±2.03 vs 14.24±2.98 mL/kg/min; P=0.521; T/E group: 13.41±2.97 vs 16.58±3.17 mL/kg/min; P=0.006). A significant correlation was found between the changes in VO2peak and the modifications in IIEF score (r=0.575; P=0.001). Conclusion. Exercise training in ED patients treated with PDE-5 inhibitors is of added valuesincefurther improves ED, as evaluated by IIEF score, and increases functional capacity.
KW - Erectile dysfunction
KW - Erectile dysfunction therapy
KW - Exercise training
KW - Metabolic syndrome
KW - Phosphodiesterase-5
UR - http://www.scopus.com/inward/record.url?scp=84937926755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937926755&partnerID=8YFLogxK
M3 - Article
C2 - 25087294
AN - SCOPUS:84937926755
VL - 80
SP - 177
EP - 183
JO - Monaldi Archives for Chest Disease
JF - Monaldi Archives for Chest Disease
SN - 1122-0643
IS - 4
ER -